Aditya Bardia, MD, MPH, on Clinical Implications of New Findings on Elacestrant vs Standard-of-Care Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer

Posted: Saturday, December 10, 2022

Aditya Bardia, MD, MPH, of Massachusetts General Hospital, discusses results from the EMERALD study, the emergence of the ESR1 mutation, and how it is involved in the development of resistance to endocrine therapy in previously treated patients. Dr. Bardia explains where elacestrant would fit in the overall treatment paradigm for patients with advanced estrogen receptor (ER)-positive, HER2-negative breast cancer.